AIMT To Face FDA Panel In Sep., FDA Lifts Hold On ADVM Trial, OTLK Jumps

Today's Daily Dose brings you news about Aimmune Therapeutics' upcoming regulatory catalyst; FDA lifting the clinical hold on OPTIC trial; Analyst rating on Outlook Therapeutics and Cellectar Biosciences' $10 million financing.

from RTT - Biotech http://bit.ly/2HuMUqg
via IFTTT